ResMed Inc. 10-K Summary: Fiscal Year Ended June 30, 1998
Business Context and Reporting Period
This report covers the fiscal year ended June 30, 1998. ResMed Inc. is a leading designer, manufacturer, and distributor of medical equipment for treating and diagnosing sleep disordered breathing (SDB), primarily obstructive sleep apnea (OSA). The company operates globally with manufacturing primarily in Sydney, Australia, and sales operations in over 40 countries. Key product lines include nasal CPAP, VPAP (bi-level), and AutoSet systems.
Key Financial Metrics
| Metric | Fiscal 1998 | Fiscal 1997 | Change |
|---|---|---|---|
| Net Revenues | $66.5 million | $49.2 million | +35% |
| Gross Profit | $43.5 million | $28.9 million | +50% |
| Gross Margin | 65.3% | 58.7% | +6.6 pts |
| Operating Income | $17.4 million | $8.3 million | +109% |
| Net Income | $10.6 million | $7.5 million | +42% |
| Diluted EPS | $1.41 | $1.02 | +38% |
| Cash & Equivalents | $15.5 million | $9.1 million | +70% |
| Working Capital | $32.8 million | $34.4 million | -5% |
| Long-Term Debt | $0 | $0.3 million | Eliminated |
Note: The company had no long-term debt as of June 30, 1998, having paid down the Australian government loan facility.
Material Changes vs. Prior Period
- Revenue Growth: Driven by a 35% increase in unit sales, particularly in North America (up to $34.3M) and Europe (up to $23.3M). Growth was also fueled by a shift to higher-priced bi-level products (VPAP) and improved mask systems.
- Margin Expansion: Gross margin improved to 65.3% from 58.7%. This was attributed to manufacturing efficiencies, a favorable product mix, and a 21% devaluation of the Australian dollar (the currency of manufacturing costs).
- Foreign Currency Impact: While the devaluation boosted gross margins, it resulted in a significant foreign currency loss of $4.0 million in "Other, net" expenses, compared to a gain of $1.6 million in the prior year.
- Capital Expenditures: Investing activities totaled $12.8 million, primarily for the construction of a new 120,000 sq. ft. manufacturing facility in Sydney, expected to be completed in early 1999.
Guidance, Outlook, and Risks
- Product Pipeline: The company is focused on the launch of AutoSet T (automatic CPAP) in late 1998 and expanding into new markets such as ventilatory assistance for lung disorders (FDA clearance received in June and August 1998).
- Legal Proceedings: Significant patent litigation continues against competitor Respironics in the U.S. and Australia. The company recently faced partial summary judgments against it in the U.S. regarding two of four patents in suit, though it intends to appeal. An Australian claim alleges unfair trade practices with damages of approximately $1 million.
- Reimbursement Risk: Success depends on third-party payors (Medicare, private insurers) reimbursing patients. The company notes increasing pressure on prices and potential denial of reimbursement if devices are deemed experimental or unnecessary.
- Year 2000 Compliance: The company is implementing Oracle Applications to ensure Y2K compliance, with estimated costs of $2.0 million for the system and $100,000 for compliance reviews.
Investor Verification Checklist
- Patent Litigation Status: Verify the outcome of the pending appeals regarding the U.S. patent infringement case against Respironics and the Australian unfair trade practices claim.
- Foreign Exchange Exposure: Assess the company's hedging strategy given the significant volatility in the Australian dollar and its impact on both margins and "Other" income/loss.
- Reimbursement Trends: Monitor changes in Medicare and private insurance reimbursement policies for CPAP and VPAP devices in the U.S. and Europe.
- New Facility Timeline: Confirm the completion date and cost overruns, if any, for the new Sydney manufacturing facility scheduled for early 1999.
- AutoSet Adoption: Track market acceptance and sales volume of the new AutoSet T automatic pressure device upon its release.